AlveoGene is a biotechnology company developing inhaled gene therapies for rare and serious respiratory diseases. Its work centres on the proprietary InGenuiTy platform, a lentiviral delivery technology designed to administer genetic medicines directly to the lungs via nebuliser or other pulmonary delivery routes. The company is building a pipeline of treatments targeting conditions with high unmet medical need, including surfactant protein deficiencies, alpha-1 antitrypsin deficiency-related lung disease and idiopathic pulmonary fibrosis. Operating in the life sciences and respiratory therapeutics industry, AlveoGene combines gene therapy, drug delivery and translational respiratory medicine to create long-lasting treatments for patients with limited options.
This is a company profile stub. Create an account to claim your profile.
Industry
BiotechnologyAreas of Focus
Location
Oxford
Status
Active
